## 3 Results  
Forty-seven patients (58.60 \(\pm\) 10.18 years; 46.81% males) with SAPS were included in the study.  
In Group 1, there were 22 patients (mean age-58.73 \(\pm\) 9.47 years; 40.91% males; 36.36% retired) and in Group 2, 25 patients (mean age-58.48 \(\pm\) 10.96 years; 52% males; 48% retired). No age, sex or symptom duration differences were observed between groups (\(p\) > 0.05). Patients' characteristics are presented in Table 1.  
There were no differences at the initial evaluation between groups on all assessments. The post treatment evaluations showed significantly better scores in Group 1 patients for VAS score (\(p\) = 0.03) and SPADI (\(p\) = 0.04). Significant improvement was seen in both groups for all scores (Table 2). The improvement seen in all patients' for VAS score (post-vs. pre-treatment) was greater than the minimally clinically important difference (MCID) reported for VAS pain score in patients with rotator cuff disease (greater than 1.4 [22]). All patients had an improvement greater than the reported MCID for SPADI (MCID between 8 and 13 [18]). A change greater than the reported MCID for the CSS score (MCID of 19 in patients with intact rotator cuff [21]) was reported in 90.9% of patients in Group 1 and only in 84% patients in Group 2.  
The changes in SPADI scores between follow-up and initial assessments were significantly greater in Group 1 compared to Group 2 (\(p\) = 0.004).  
\begin{table}
\begin{tabular}{c c c c} \hline \hline  & **Group 1 (\(n\) = 22)** & **Group 2 (\(n\) = 25)** & \(p\) ** \\ \hline \hline Age, years (mean \(\pm\) SD) & 58.73 \(\pm\) 9.47 & 58.48 \(\pm\) 10.96 & 0.93 \\ Sex & & & \\ Female, \(n\)(\%) & 13 (59.09) & 12 (48) & 0.57 \\ Male, \(n\)(\%) & 9 (40.91) & 13 (52) & \\ Occupation & & & \\ Active, \(n\)(\%) & 14 (63.64) & 13 (52) & 0.55 \\ Retired, \(n\)(\%) & 8 (36.36) & 12 (48) & \\ Affected shoulder & & & \\ Right, \(n\)(\%) & 11 (50) & 16 (64) & 0.38 \\ Left, \(n\)(\%) & 11 (50) & 9 (36) & \\ Pathology & & & \\ \multicolumn{3}{l}{Calcified dentiitis, \(n\)(\%)} & 15 (68.18) & 18 (72) & 0.99 \\ Adhesive capsulitis, \(n\)(\%) & 7 (31.82) & 7 (28) & \\ Symptom duration, days (mean \(\pm\) SD) & 137.7 \(\pm\) 23.37 & 134.2 \(\pm\) 20.17 & 0.59 \\ \hline \hline \end{tabular}
\end{table}
Table 1: Patients’ characteristics.  
\begin{table}
\begin{tabular}{c c c c c c} \hline \hline  & **Group 1 (\(n\) = 22)** & **Group 2 (\(n\) = 25)** & \(p\) ** & **95\% CI** \\ \hline \hline VAS (median [IQR]) & \multicolumn{3}{c}{\(p\) *} & \multicolumn{3}{c}{\(p\) *} & \\ Baseline & 8 [7–8.25] & \textless{}0.0001 & 8 [8–9] & 0.16 & 0–1 \\ Follow-up & 3 [2–4] & \textless{}0.0001 & 4 [3–6] & 0.03 & 0–2 \\ Change & 5 [3–6] & & 4 [3–7] & 0.11 & 0–2 \\ CSS (mean \(\pm\) SD) & & & & \\ Baseline & 26.27 \(\pm\) 11.7 & \textless{}0.0001 & 22.56 \(\pm\) 9.86 & & 0.24 & \(-\)2.62–10.05 \\ Follow-up & 63.09 \(\pm\) 18.14 & \textless{}0.0001 & 54.04 \(\pm\) 17.64 & \textless{}0.0001 & 0.09 & \(-\)1.47–19.58 \\ Change & 36.82 \(\pm\) 16.58 & & 31.08 \(\pm\) 11.4 & & 0.16 & \(-\)2.53–14.02 \\ SPADI (mean \(\pm\) SD) & & & & & \\ Baseline & 67.86 \(\pm\) 14.04 & \textless{}0.0001 & 66.89 \(\pm\) 12.5 & & \\ Follow-up & 22.9 \(\pm\) 16.76 & \textless{}0.0001 & 33.34 \(\pm\) 17.08 & \textless{}0.0001 & 0.8 & \(-\)8.76–6.82 \\ Change & 44.96 \(\pm\) 16.5 & & & & \\ \hline \hline \end{tabular}
\end{table}
Table 2: Patients’ assessments before and after treatments.